1)Guidelines on Testicular Cancer, European Association of Urology, 2014
2)Leibovitch L, Foster RS, Kopecky KK, et al:Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 154:1759-1763, 1995
3)de Wit M, Brenner W, Hartmann M, et al:[18F]-FDG-PET in clinical stage Ⅰ/Ⅱ non-seminomatous germ cell tumours:results of the German multicentre trial. Ann Oncol 19:1619-1623, 2008
4)Albers P, Bender H, Yilmaz H, et al:Positron emission tomography in the clinical staging of patients with Stage Ⅰ and Ⅱ testicular germ cell tumors. Urology 53:808-811, 1999
5)Sanchez D, Zudaire JJ, Fernandez JM, et al:18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int 89:912-916, 2002
6)Divrik RT, Akdogan B, Ozen H, et al:Outcomes of surveillance protocol of clinical stage Ⅰ nonseminomatous germ cell tumors-is shift to risk adapted policy justified? J Urol 176:1424-1430, 2006
7)Tandstad T, Dahl O, Cohr-Cedermark G, et al:Risk-adapted treatment in clinical stage Ⅰ nonseminomatous germ cell testicular cancer:the SWENOTECA management program. J Clin Oncol 27:2122-2228, 2009
8)Sturgeon JF, Moore MJ, Kakiashvili DM, et al:Non-risk-adapted surveillance in clinical stage Ⅰ nonseminomatous germ cell tumors:the Princess Margaret Hospial's experience. Eur Urol 59:556-562, 2011
9)Oechsle K, Hartmann M, Brenner W, et al:[18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy:the German multicenter positron emission tomography study group. J Clin Oncol 26:5930-5935, 2008
10)De Santis M, Becherer A, Bokemeyer C, et al:2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma:an update of the prospective multicentric SEMPET trial. J Clin Oncol 22:1034-1039, 2004
11)Hinz S, Schrader M, Kempkensteffen C, et al:The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol 179:936-940, 2008
12)Jeurkar N, Mamtani R, Vaughn DJ:Granulomatosis and testicular germ cell tumors. Urology 80:1303-1306, 2012
13)Kailani W, Boyle H, Chatte G et al:Sarcoid-like granulomatosis and testicular germ cell tumor:the‘Great Imitator’. Oncology 81:319-324, 2011
fluoro-deoxy-D-glucose positron emission tomography(FDG-PET)for postchemotherapy seminoma residual lesions:a retrospective validation of the SEMPET trial. Ann Oncol 23:59-64, 2012
15)Bokemeyer C, Kollmannsberger C, Oechsle K, et al:Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using[(18)F]FDG PET. Br J Cancer 86:506-511, 2002